Literature DB >> 22217740

Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM.

Renato Goreshi1, Joyce Okawa, Matt Rose, Rui Feng, Lela A Lee, Christopher B Hansen, Carolyn A Bangert, M Kari Connolly, Mark D Davis, Jeff P Callen, Nicole M Fett, Steven S Fakharzadeh, Jennie T Clarke, Victoria P Werth.   

Abstract

To properly evaluate therapies for cutaneous dermatomyositis (DM), it is essential to administer an outcome instrument that is reliable, valid, and responsive to clinical change, particularly when measuring disease activity. The purpose of this study was to compare two skin severity DM outcome measures, the Cutaneous Disease and Activity Severity Index (CDASI) and the Cutaneous Assessment Tool-Binary Method (CAT-BM), with the Physician Global Assessment (PGA) as the "gold standard". Ten dermatologists evaluated 14 patients with DM using the CDASI, CAT-BM, and PGA scales. Inter- and intra-rater reliability, validity, responsiveness, and completion time were compared for each outcome instrument. Responsiveness was assessed from a different study population, where one physician evaluated 35 patients with 110 visits. The CDASI was found to have a higher inter- and intra-rater reliability. Regarding construct validity, both the CDASI and the CAT-BM were significant predictors of the PGA scales. The CDASI had the best responsiveness among the three outcome instruments examined. The CDASI had a statistically longer completion time than the CAT-BM by about 1.5 minutes. The small patient population may limit the external validity of the findings observed. The CDASI is a better clinical tool to assess skin severity in DM.

Entities:  

Mesh:

Year:  2012        PMID: 22217740      PMCID: PMC3752293          DOI: 10.1038/jid.2011.440

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  22 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Reliability: on the reproducibility of assessment data.

Authors:  Steven M Downing
Journal:  Med Educ       Date:  2004-09       Impact factor: 6.251

3.  Evaluating changes in health status: reliability and responsiveness of five generic health status measures in workers with musculoskeletal disorders.

Authors:  D E Beaton; S Hogg-Johnson; C Bombardier
Journal:  J Clin Epidemiol       Date:  1997-01       Impact factor: 6.437

4.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

Review 5.  Dermatomyositis.

Authors:  Jeffrey P Callen; Robert L Wortmann
Journal:  Clin Dermatol       Date:  2006 Sep-Oct       Impact factor: 3.541

6.  Agreement between multi-dimensional and renal-specific response criteria in patients with juvenile systemic lupus erythematosus and renal disease.

Authors:  Nicolino Ruperto; Anna Bazso; Angela Pistorio; Angelo Ravelli; Giovanni Filocamo; Hayde Guadalupe Hernandez Huirache; Ana Luisa Rodriguez Lozano; Alejandra Beatriz Pringe; Iris Vilca; Alberto Martini
Journal:  Clin Exp Rheumatol       Date:  2010-06-23       Impact factor: 4.473

Review 7.  Psoriasis assessment tools in clinical trials.

Authors:  S R Feldman; G G Krueger
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

8.  Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis.

Authors:  B Kunz; A P Oranje; L Labrèze; J F Stalder; J Ring; A Taïeb
Journal:  Dermatology       Date:  1997       Impact factor: 5.366

9.  Scalp involvement in dermatomyositis. Often overlooked or misdiagnosed.

Authors:  J S Kasteler; J P Callen
Journal:  JAMA       Date:  1994-12-28       Impact factor: 56.272

Review 10.  A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies.

Authors:  Pedram Gerami; Jennifer M Schope; Lauren McDonald; Hobart W Walling; Richard D Sontheimer
Journal:  J Am Acad Dermatol       Date:  2006-01-23       Impact factor: 11.527

View more
  19 in total

Review 1.  Classification of myositis.

Authors:  Ingrid E Lundberg; Marianne de Visser; Victoria P Werth
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

2.  Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists.

Authors:  J Tiao; R Feng; E M Berger; J F Brandsema; C C Coughlin; N Khan; E A Kichula; M A Lerman; S Lvovich; P J McMahon; L G Rider; A I Rubin; L V Scalzi; D M Smith; A J Taxter; J R Treat; R P Williams; S W Yum; J Okawa; V P Werth
Journal:  Br J Dermatol       Date:  2017-07-31       Impact factor: 9.302

3.  Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change.

Authors:  C O Anyanwu; D F Fiorentino; L Chung; C Dzuong; Y Wang; J Okawa; K Carr; K J Propert; V P Werth
Journal:  Br J Dermatol       Date:  2015-08-11       Impact factor: 9.302

4.  The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists.

Authors:  J Tiao; R Feng; S Bird; J K Choi; J Dunham; M George; T C Gonzalez-Rivera; J L Kaufman; N Khan; J J Luo; R Micheletti; A S Payne; R Price; C Quinn; A I Rubin; A G Sreih; P Thomas; J Okawa; V P Werth
Journal:  Br J Dermatol       Date:  2016-12-22       Impact factor: 9.302

Review 5.  The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: A comprehensive review.

Authors:  S Ahmed; K L Chen; V P Werth
Journal:  Semin Arthritis Rheum       Date:  2020-01-11       Impact factor: 5.532

6.  Inter-rater reliability of cutaneous sarcoidosis assessment tools via remote photographic assessment.

Authors:  Sara A Berg; Howa Yeung; Joseph C English; Emily L Keimig; Ellen J Kim; Robert G Micheletti; Karolyn A Wanat; Marc A Judson; Robert P Baughman; Misha Rosenbach
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

7.  Update on Epidemiology and Clinical Assessment Tools of Cutaneous Lupus Erythematosus and Dermatomyositis.

Authors:  Yunyoung C Chang; Victoria P Werth
Journal:  Curr Dermatol Rep       Date:  2013-01-24

8.  Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis.

Authors:  Paige W Wolstencroft; Lorinda Chung; Shufeng Li; Livia Casciola-Rosen; David F Fiorentino
Journal:  JAMA Dermatol       Date:  2018-01-01       Impact factor: 10.282

9.  Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis.

Authors:  Misha Rosenbach; Howa Yeung; Emily Y Chu; Ellen J Kim; Aimee S Payne; Junko Takeshita; Carmela C Vittorio; Karolyn A Wanat; Victoria P Werth; Joel M Gelfand
Journal:  JAMA Dermatol       Date:  2013-05       Impact factor: 10.282

Review 10.  Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI).

Authors:  Lisa G Rider; Victoria P Werth; Adam M Huber; Helene Alexanderson; Anand Prahalad Rao; Nicolino Ruperto; Laura Herbelin; Richard Barohn; David Isenberg; Frederick W Miller
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.